Bladder cancer transitional cell

Conzelman GM Jr et al Induction of transitional cell carcinomas of the urinary bladder in monkeys fed 2-naphthylamine. J Natl Cancer Inst 41 15- 56, 1969... 

K. Radiation therapy and concomitantpaclitaxel/carboplatin chemotherapy formuscle invasive transitional cell carcinoma of the bladder a well-tolerated combination. Int J Cancer 2000 90(5) 281-286. 

Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994 73 1926-1931. 

Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder an analysis of survival and control. IntJ Rad Oncol Biol Phys 1986 12 853-860. 

Kyriazis AP, Yagoda A, Kereiakes JG. Experimental studies on the radiation-modifying effect of cis-diamminedichloroplatinum II (DDP) in human bladder transitional cell carcinomas grown in nude mice. Cancer 1983 52 452-457. 

Jakse G, Frommhold H, Nedden DZ. Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder. Cancer 1985 55 1659-1664. 

Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000 6 2424—2430. 

Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999 15 5647-5650. 

Preliminary in vitro and animal studies of the effects of silymarin and silybinin have been carried out with several cancer cell lines. In murine models of skin cancer, silybinin and silymarin were said to reduce tumor initiation and promotion. Induction of apoptosis has also been reported using silymarin in a variety of malignant human cell lines (eg, melanoma, prostate, leukemia cells, bladder transitional-cell papilloma cells, and hepatoma cells). Inhibition of cell growth and proliferation by inducing a Gx cell cycle arrest has also been claimed in cultured human breast and prostate cancer cell lines. The use of milk thistle in the clinical treatment of cancer has not yet been adequately studied but preliminary trials are under way. 

In addition to its use in preventing tuberculosis, BCG has been used as an immunostimulant or immunomodulator. The degree of safety of this procedure differs with the technique and the purpose for which it is used. In most areas, the use of BCG to counter cancer has proved disappointing, although it is still used to some extent, generally as an adjunct to other forms of treatment (1-7). More encouraging is the nse of intravesical instillation of BCG for recnrrent snperficial transitional cell carcinoma of the bladder, for which it now constitutes the treatment of choice. 

Intravesical instillation of BCG has been nsed to treat superficial bladder carcinoma and interstitial cystitis. Many reports have confirmed the efficacy of BCG in the treatment of transitional cell bladder cancers and have delineated its adverse effects (SEDA-12, 273) (SEDA-13, 278) (SEDA-15, 344) (SEDA-16, 375) (SEDA-17, 366) (SEDA-18, 328) (SEDA-20, 287) (SEDA-21, 328) (SEDA-22, 336). The exact mechanism of its antitumor activity is unknown, but live BCG provokes an inflammatory response that includes activation of macrophages, a delayed hypersensitivity reaction, and stimulation of T and B lymphocytes and natural killer cells. 

Birlik M, Akar S, Tuzel E, Onen F, Ozer E, Manisali M, Kirkali Z, Akkoc N. Gemcitabine-induced vascuhtis in advanced transitional cell carcinoma of the bladder. 1 Cancer Res Clin Oncol 2004 130(2) 122-5. 

Sarkis, A., Dalbagni, G., Cordon-Cardo, C Zhang, Z.-F., Sheinfeld, J., Fair, W., Herr, H and Reuter, V. (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma a marker for disease progression. J. Natl. Cancer Inst. 85, 53-59. 

Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, et al. 2000. Pacli-taxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6 4874-84... 

Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003 169 2101. 

Moderate atypia and atypical hyperplasia of the urothelium were first described in 4 pieces of nephroureterectomies performed in 3 CHN patients prior or at time of transplantation [28]. Then, three cases of cancers of the urinary tract were reported the first case, a 28 year old woman with CHN, developed two papillary transitional cell carcinomas in the posterior bladder wall 12 months after a renal transplantation [31] the second case, a 42 year old woman with CHN, presented with hematuria secondary to a papillary transitional cell carcinoma of the right pelvis [32]. The third case was a 49 year old woman previously published as... 

Prodnction and characterization of Re-188-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med 42 726-732... 

Durkan, G. C., Nutt, J. E., Rajjayabun, P. H., Neal, D. E., Lunec, J., and Mellon, J. K., Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin. Cancer Res. 7, 3450-3456 (2001). 

M6. Margulies, I. M., Urinary type IV collagenase Elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiology, Biomarkers, Prevention 1, 467 74 (1992). 

Yuasa, T., Yoshiki, T., Isono, T. et al. (1999) Expression of transitional cell-specific genes, uroplakin la and II, in bladder cancer detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol, 6, 286-292. 

---